Expression of D3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: Effect of levodopa treatment

Neuroscience

Volumn 98, Issue 2, 2000, Pages 263-273

  Quik, M ^a   Police, S ^a   He, L ^a   Di Monte, D A ^a   Langston, J W ^a  

^a PARKINSON S INSTITUTE   (United States)

Author keywords

Basal ganglia; D3 dopamine receptors; L DOPA; Monkey; MPTP; Parkinson s disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE 3 RECEPTOR; LEVODOPA; MESSENGER RNA; POSTSYNAPTIC RECEPTOR;

ANIMAL CELL; ARTICLE; AUTORADIOGRAPHY; BASAL GANGLION; BINDING SITE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DYSKINESIA; MONKEY; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR BINDING; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BEHAVIOR, ANIMAL; BINDING SITES; CARRIER PROTEINS; CAUDATE NUCLEUS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; LEVODOPA; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NEOSTRIATUM; NERVE TISSUE PROTEINS; PARKINSONIAN DISORDERS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RNA, MESSENGER; SAIMIRI; SUBSTANTIA NIGRA;

EID: 0034087140     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(00)00130-5     Document Type: Article

References (57)

1. Albin R.L., Young A.B., Penny J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12:1989;366-375.
2. Alexander G.M., Brainard D.L., Gordon S.W., Hichens M., Grothusen J.R., Schwartzman R.J. Dopamine receptor changes in untreated and (+)-PHNO-treated MPTP parkinsonian primates. Brain Res. 547:1991;181-189.
3. Alexander G.M., Schwartzman R.J., Brainard L., Gordon S.W., Grothusen J.R. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP Parkinsonism in monkeys. Brain Res. 588:1992;261-269.
4. Alexander G.M., Schwartzman R.J., Grothusen J.R., Brainard L., Gordon S.W. Changes in brain dopamine receptors in MPTP Parkinsonism monkeys following L-DOPA treatment. Brain Res. 625:1993;276-282.
5. Blanchet P.J., Konitiotis S., Chase T.N. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa primed 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine monkeys. J. Pharmac. exp. Ther. 283:1997;794-799.
6. 125I]Iodophenyl)tropane-2β-carboxylic acid isopropyl ester. Molec. Pharmac. 47:1995;779-786.
7. 3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. natn. Acad. Sci. U.S.A. 94:1997;3363-3367.
8. 2 receptor mRNA. Brain Res. 564:1991;203-219.
9. Boyce S., Rupniak N.M., Steventon M.J., Iversen S.D. Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. Clin. Neuropharmac. 13:1990;448-458.
10. Chesselet M-F., Delfs J.M. Basal ganglia and movement disorders: an update. Trends Neurosci. 19:1996;417-422.
11. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain. 122:1999;1437-1448.
12. DeLong M.R. Primate models of movement disorder of basal ganglia origin. Trends Neurosci. 13:1990;281-285.
13. 3 receptor in the rat brain. Neurosci. 65:1995;731-745.
14. Di Chiara G., Morelli M., Consolo S. Modulatory functions of neurotransmitters in the striatum: Ach/dopamine/NMDA interactions. Trends Neurosci. 17:1994;228-233.
15. Di Monte D.A., McCormick A., Petzinger G., Janson A.M., Quik M., Langston J.W. Nigrostriatal degeneration, Parkinsonism and dyskinesia in the squirrel monkey. Soc. Neurosci. Abstr. 29:1999;1339.
16. Emmers R., Akert K. A stereotaxic atlas of the brain of the squirrel monkey (Saimiri sciureus). 1963;Wisconsin, Madison.
17. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 114:1991;2283-2301.
18. 1 receptors in drug-naive MPTP monkeys. Brain Res. 719:1996;129-137.
19. Graham W.C., Sambrook M.A., Crossman A.R. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in monkey brain in MPTP-induced Parkinsonism. Brain Res. 602:1993;290-303.
20. Henry B., Crossman A.R., Brotchie J.M. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Expl Neurol. 151:1998;334-342.
21. 3H]PD 128907 in the caudate-putamen of the adult rat. Brain Res. 822:1999;126-131.
22. 3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment. Brain Res. 709:1996;259-264.
23. 3 Receptor expression within the basal ganglia is not affected by Parkinson's disease. Neurosci. Lett. 214:1996;75-78.
24. Jaber M., Robinson S.W., Missale C., Caron M.G. Dopamine receptors and brain function. Neuropharmacology. 35:1996;1503-1519.
25. 3 receptor sites in rat brain: a comparative study using in situ hybridization histochemistry and ligand binding autoradiography. Eur. J. Neurosci. 5:1993;145-153.
26. 3 receptor mRNA and binding sites in human brain. Mol. Brain Res. 18:1993;187-192.
27. Langston J. W., Quik M., Petzinger G., Jakowec M. and Di Monte D. (1999) Investigating levodopa-induced dyskinesias in the parkinsonian primate. Ann. Neurol. (in press).
28. 3 dopamine receptor: neurobiology and potential clinical relevance. Pharmac. Rev. 49:1997;231-252.
29. 3 dopamine receptors in the brains of several mammalian species. Brain Res. 800:1998;269-274.
30. 3H]-hydroxy-N, N-di-n-propyl-2-aminotetralin. Proc. natn. Acad. Sci. U.S.A. 89:1992;8155-8159.
31. Levy R., Hazrati L.-N., Herrero M.-T., Vila M., Hassani O.-K., Mouroux M., Ruberg M., Asensi H., Agid Y., Feger J., Obeso J.A., Parent A., Hirsch E.C. Re-evaluation of the functional anatomy of the basal ganglia in normal and parkinsonian states. Neurosci. 76:1997;335-343.
32. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 78:1998;189-225.
33. Morissette M., Goulet M., Calon F., Falardeau P., Blanchet P., Bedard P.J., Di Paolo T. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine: correction with chronic administration of L-3, 4-dihydroxyphenylalamine. Molec. Pharmac. 50:1996;1073-1079.
34. 3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur. J. Neurosci. 10:1998;2565-2573.
35. Parent A., Mackey A., Smith Y., Boucher R. The output organization of the substantia nigra in primate as revealed by retrograde double labeling method. Brain. Res. Bull. 10:1983;529-537.
36. Parent A., Smith Y., De Bellefeuille L. The output organization of the pallidum and substantia nigra in primate as revealed by retrograde double labeling method. McKenzie J.S., Kemm R.E., Wilcock L.N. The Basal Ganglia. 1984;Plenum, New York.
37. Piercey M.F., Hoffmann W.E., Smith M.W., Hyslop D.K. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor preferring agonist; comparison to other dopamine agonists. Eur. J. Pharmacol. 312:1996;35-44.
38. Piercey M.F. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin. Neuropharmac. 21:1998;141-151.
39. Piggott M.A., Marshall E.F., Thomas N., Lloyd S., Court J.A., Jaros E., Burn D., Johnson M., Perry R.H., McKeith I.G., Ballard C., Perry E.K. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain. 122:1999;1449-1468.
40. Pinter M.M., Pogarell O., Oertel W.H. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J. Neurol. Neurosurg. Psychiat. 66:1999;436-441.
41. 3 agonist PD 128907. J. Pharmac. exp. Ther. 275:1995;55-66.
42. Rioux L., Frohna P.A., Joyce J.N., Schneider J.S. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys. Mov. Disord. 12:1997;148-158.
43. Robertson G.S., Robertson H.A. Evidence that L-DOPA induced torational behavior is dependent on both striatal and nigral mechanisms. J. Neurosci. 9:1989;3326-3331.
44. Robertson H.A. Dopamine receptor interactions: some implications for the treatment of Parkinson's disease. Trends Neurosci. 15:1992;201-206.
45. 2 receptor is elevated in the striatum of Parkinson's disease. Mov. Disord. 13:1998;788-797.
46. 3 receptor antagonist attenuates locomotion in rodents. J. Pharmacol. exp. Ther. 275:1995;1239-1246.
47. Schneider J.S. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol. Biochem. Behav. 34:1989;193-196.
48. 3 receptor coexistence. Brain Res. Rev. 26:1998;236-242.
49. 3 Receptor relationships in brain coexpression, coactivation and coregulation. Adv. Pharmac. 42:1998;408-411.
50. Smith A.D., Bolam J.P. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci. 13:1990;259-265.
51. 3) as a target for neuroleptics. Nature. 347:1990;146-151.
52. 3 receptors in the nucleus accumbens of the rat. Neurosci. Lett. 223:1997;13-16.
53. 3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res. 779:1998;58-74.
54. 3 receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J. Neural Transm. 94:1993;11-19.
55. 3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behavior. J. Neural. Transm. 98:1994;39-55.
56. Wichmann T., DeLong M.R. Functional and pathophysiological models of the basal ganglia. Curr. Opin. Neurobiol. 6:1996;751-758.
57. Wonnacott S. The paracox of nicoitnic acetylcholine receptor upregualtion by nicotine. Trends pharmac. Sci. 11:1991;216-219.